Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27.551
Filter
2.
Med Mycol J ; 65(2): 33-38, 2024.
Article in English | MEDLINE | ID: mdl-38825528

ABSTRACT

Antifungal stewardship (AFS), compared with antimicrobial stewardship (AS), requires more advanced knowledge, skills, and multidisciplinary collaboration in its implementation. Therefore, fewer facilities are performing AFS compared with AS. At our hospital, we started AS and AFS in 2014. Our AFS programs include the following: i) interventions for patients with yeast-positive blood cultures, ii) introduction of a conditional antifungal notification system, and iii) commencement of AS team rounds. AFS for filamentous fungi includes bronchoscopy and microbial identification, including genetic and drug susceptibility testing. These AFS activities have improved several processes and outcome measures. However, our AFS team has faced several problems owing to the impact of COVID-19. This review introduces the practice of AFS, which we initiated at our hospital in 2014, and presents the current problems.


Subject(s)
Antifungal Agents , Antimicrobial Stewardship , Hospitals, University , Humans , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Antimicrobial Stewardship/methods , Japan , COVID-19 , SARS-CoV-2/drug effects , Mycoses/drug therapy
3.
Mycoses ; 67(6): e13751, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38825584

ABSTRACT

BACKGROUND: Kerion is a severe type of tinea capitis that is difficult to treat and remains a public health problem. OBJECTIVES: To evaluate the epidemiologic features and efficacy of different treatment schemes from real-world experience. METHODS: From 2019 to 2021, 316 patients diagnosed with kerion at 32 tertiary Chinese hospitals were enrolled. We analysed the data of each patient, including clinical characteristics, causative pathogens, treatments and outcomes. RESULTS: Preschool children were predominantly affected and were more likely to have zoophilic infection. The most common pathogen in China was Microsporum canis. Atopic dermatitis (AD), animal contact, endothrix infection and geophilic pathogens were linked with kerion occurrence. In terms of treatment, itraconazole was the most applied antifungal agent and reduced the time to mycological cure. A total of 22.5% of patients received systemic glucocorticoids simultaneously, which reduced the time to complete symptom relief. Furthermore, glucocorticoids combined with itraconazole had better treatment efficacy, with a higher rate and shorter time to achieving mycological cure. CONCLUSIONS: Kerion often affects preschoolers and leads to serious sequelae, with AD, animal contact, and endothrix infection as potential risk factors. Glucocorticoids, especially those combined with itraconazole, had better treatment efficacy.


Subject(s)
Antifungal Agents , Itraconazole , Microsporum , Tinea Capitis , Humans , Child, Preschool , Antifungal Agents/therapeutic use , Male , Female , Tinea Capitis/drug therapy , Tinea Capitis/epidemiology , Tinea Capitis/microbiology , Itraconazole/therapeutic use , China/epidemiology , Microsporum/isolation & purification , Child , Infant , Glucocorticoids/therapeutic use , Treatment Outcome , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/epidemiology , Dermatitis, Atopic/microbiology , Risk Factors , Adolescent , Adult , Middle Aged , Retrospective Studies
4.
Lakartidningen ; 1212024 Jun 03.
Article in Swedish | MEDLINE | ID: mdl-38828641

ABSTRACT

This text discusses a rare case of soft tissue infection caused by the fungus Saksenaea in a young, immunocompetent woman following an all-terrain vehicle accident abroad. Despite initial treatment, her wound worsened, necessitating multiple surgical revisions and aggressive antifungal therapy with liposomal Amphotericin B. The interdisciplinary collaboration among orthopedic surgeons, infectious disease specialists, and plastic surgeons played a vital role in her successful treatment. Prompt identification of the fungus and immediate intervention were crucial. This case emphasizes the importance of awareness among healthcare providers regarding this rare condition and underscores the significance of early diagnosis and timely surgical and medical interventions for a positive outcome.


Subject(s)
Amphotericin B , Antifungal Agents , Immunocompetence , Humans , Female , Antifungal Agents/therapeutic use , Amphotericin B/therapeutic use , Accidents, Traffic , Mucormycosis/diagnosis , Mucormycosis/drug therapy , Soft Tissue Infections/microbiology , Soft Tissue Infections/drug therapy , Soft Tissue Infections/diagnosis , Invasive Fungal Infections/drug therapy , Invasive Fungal Infections/diagnosis , Adult , Mucorales/isolation & purification
5.
Saudi Med J ; 45(6): 606-616, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38830660

ABSTRACT

OBJECTIVES: To assess the risk variables related to the types of candidemia for each patient, who was admitted into the intensive care unit regardless of the patient with or without complete diagnosis of COVID-19, during the period of March 2019 to December 2022. METHODS: The evaluation comparison of demographic and clinical data of COVID-19 positive and negative patients with candidemia confirmed in blood, 113 cases were assessed. Variables such as gender, age, age of hospitalization, history of hospitalization, concurrently infection, The acute physiology and chronic health evaluation-II scores, comorbidity checking, intubation, central venous catheter use, parenteral nutrition use, steroid use, antibiotic use, lymphopenia, and laboratory variables were evaluated. Candida species distribution, antifungal susceptibility in blood culture were determined. RESULTS: Coronavirus disease-19 was present in 62.8% of cases confirmed candidemia, and these cases were significantly different from COVID-19 negative cases. Significance was found in more intubation, central venous catheter use, parenteral nutrition, and steroid therapy in Group 2. There was no significance with species distribution and associated infection. In total, COVID-19 positive had higher hemoglobin, aspartate aminotransferase, alanine transaminase, and white blood cell levels, which may be associated with the possibility of revealing and controlling candidemia. CONCLUSION: Candida albicans and Candida Parapsilosis (C. parapsilosis) are the species seen in infected COVID-19 patients, while C. parapsilosis and Candida tropicalis are found in non-COVID-19 ones. Risk factors were intubation, parenteral nutrition, central venous catheter, and steroid in the COVID-19 group.


Subject(s)
COVID-19 , Candida , Candidemia , Intensive Care Units , Humans , Candidemia/epidemiology , Risk Factors , Male , Female , Intensive Care Units/statistics & numerical data , COVID-19/complications , COVID-19/epidemiology , Middle Aged , Candida/isolation & purification , Aged , Adult , Parenteral Nutrition , Candida albicans/isolation & purification , Antifungal Agents/therapeutic use , SARS-CoV-2 , Candida tropicalis/isolation & purification
7.
BMC Ophthalmol ; 24(1): 234, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38831303

ABSTRACT

BACKGROUND: Ochrobactrum anthropi is widely distributed and primarily infects patients with compromised immune functions . Historically, O. anthropi has been considered to possess low toxicity and pathogenicity; however, recent studies suggest that it may in fact cause severe purulent infections. In this case study, we examine a case of O. anthropi infection following corneal transplantation, exploring the occurrence and outcomes of such post-operative infections. CASE PRESENTATION: A retrospective analysis of cases involved examinations, genetic testing for diagnosis, and subsequent treatment. In patients undergoing partial penetrating keratoplasty with a fungal corneal ulcer perforation, anterior chamber exudation and purulence were observed post-surgery. Despite antifungal treatment, genetic testing of the anterior chamber fluid and purulent material confirmed O. anthropi infection. The use of antimicrobial treatment specifically targeting O. anthropi was found to be effective in treating the infection. CONCLUSION: Inflammatory reactions following corneal transplantation should be should be monitored for the presence of other infections. Genetic testing has significant implications for clinical diagnosis and treatment.


Subject(s)
Eye Infections, Bacterial , Gram-Negative Bacterial Infections , Ochrobactrum anthropi , Humans , Ochrobactrum anthropi/isolation & purification , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/etiology , Eye Infections, Bacterial/diagnosis , Eye Infections, Bacterial/microbiology , Eye Infections, Bacterial/etiology , Male , Keratoplasty, Penetrating/adverse effects , Corneal Ulcer/microbiology , Corneal Ulcer/diagnosis , Corneal Ulcer/etiology , Corneal Transplantation/adverse effects , Female , Middle Aged , Antifungal Agents/therapeutic use
8.
Mycoses ; 67(5): e13728, 2024 May.
Article in English | MEDLINE | ID: mdl-38695201

ABSTRACT

BACKGROUND: Fungal keratitis is a severe eye infection that can result in blindness and visual impairment, particularly in developing countries. Fusarium spp. are the primary causative agents of this condition. Diagnosis of Fusarium keratitis (FK) is challenging, and delayed treatment can lead to serious complications. However, there is limited epidemiological data on FK, especially in tropical areas. OBJECTIVES: This study aimed to describe the clinical, laboratorial and epidemiological characteristics of FK in a tropical semi-arid region of Brazil. PATIENTS/METHODS: Adult patients with laboratory-confirmed FK diagnosed between October 2019 and March 2022 were evaluated. Fusarium isolates were characterized at molecular level and evaluated regarding antifungal susceptibility. RESULTS: A total of 226 clinical samples from patients suspected of keratitis were evaluated; fungal growth was detected in 50 samples (22.12%); out of which 42 were suggestive of Fusarium spp. (84%). Molecular analysis of a randomly selected set of 27 isolates identified F. solani species complex (n = 14); F. fujikuroi sensu lato (n = 6) and F. dimerum sensu lato (n = 7); a total of 10 haplotypes were identified among the strains. All but one Fusarium strains were inhibited by amphotericin B, natamycin and fluconazole. Most patients were male (71.42%; 30 out of 42), aged from 27 to 73 years old. Trauma was the most important risk factor for FK (40.47%; 17 out of 42). Patients were treated with antifungals, corticoids and antibiotics; keratoplasty and eye enucleation were also performed. CONCLUSIONS: The study provided insights into the characteristics of FK in tropical regions and emphasized the importance of enhanced surveillance and management strategies.


Subject(s)
Antifungal Agents , Eye Infections, Fungal , Fusariosis , Fusarium , Keratitis , Microbial Sensitivity Tests , Humans , Brazil/epidemiology , Fusarium/genetics , Fusarium/drug effects , Fusarium/isolation & purification , Fusarium/classification , Male , Female , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Adult , Keratitis/microbiology , Keratitis/epidemiology , Keratitis/drug therapy , Middle Aged , Fusariosis/microbiology , Fusariosis/epidemiology , Fusariosis/drug therapy , Eye Infections, Fungal/microbiology , Eye Infections, Fungal/epidemiology , Eye Infections, Fungal/drug therapy , Aged , Young Adult , Adolescent , Tropical Climate , Aged, 80 and over , Amphotericin B/pharmacology , Amphotericin B/therapeutic use
10.
J Infect Dev Ctries ; 18(4): 636-639, 2024 Apr 30.
Article in English | MEDLINE | ID: mdl-38728631

ABSTRACT

INTRODUCTION: Kodamaea ohmeri is a rare, recognized pathogen that has previously been isolated from environmental sources. The patients commonly affected by this yeast include immunocompromised as well as immunocompetent patients having several associated risk factors. METHODOLOGY: We report three cases in which K. ohmeri was isolated from blood using Bact T/ALERT. Identification was carried out by MALDI-TOF MS (Vitek-MS, BioMérieux, Marcy-l'Etoile, France) in addition to color characteristics on chromogenic media. The patients had diminished immune response on account of a multitude of comorbidities. RESULTS: K. ohmeri can be misidentified as Candida tropicalis, Candida albicans, or Candida hemolounii by conventional methods; correct and timely identification can be achieved by MALDI-TOF MS. Antifungal susceptibility breakpoints for K. ohmeri are currently not defined. An Echinocandin was added to the treatment regimen of all three of the cases. CONCLUSIONS: Identification of K. ohmeri using conventional methods is difficult and unusual yeasts should be carefully observed, especially upon prolonged incubation.


Subject(s)
Antifungal Agents , Immunocompromised Host , Saccharomycetales , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Humans , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Male , Saccharomycetales/isolation & purification , Saccharomycetales/drug effects , Female , Middle Aged , Aged , Invasive Fungal Infections/drug therapy , Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/microbiology , Microbiological Techniques
12.
Prev Vet Med ; 227: 106211, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38691954

ABSTRACT

Sporotrichosis is a widespread fungal infection that affects skin and subcutaneous tissues in humans and animals. In cats, it is displayed as nodules, ulcers and lesions on the nasal and respiratory mucosa. Antifungal treatment of cats is crucial but many cases are difficult, thus resulting in discontinue of the treatment, with disastrous consequences for the animal, encouraging contamination of the environment, other animals and people. The effects of responsible ownership education and health education for owners of cats with feline sporotrichosis as well as the interval between veterinary consultations on treatment outcomes for three groups of owners and their pet cats were evaluated in this study. The responsible ownership education and health education strategies consisted in videos in easy and accessible language for people with any level of education and were presented during consultations for two of the three groups included. The time between appointments was two weeks for two of the groups, and four weeks for one of the groups. The median of treatment time for the group without educational activities was 138 days, while for the other two groups it was 77.5 days and 86 days. It was found a significative reduction in the treatment time in the groups exposed to Responsible ownership education videos. There was no contamination of those responsible for home treatment, and the interval between monthly appointments did not impact on cure or death rates compared to the interval between fortnightly appointments. All these results can be applied to feline sporotrichoses treatment protocols increasing the owners treatment adherence and reducing either, the treatment discontinuation and the treatment costs and helps to control zoonotic sporotrichosis. The importance of attractive and comprehensible educational strategies as part of the feline sporotrichosis treatment protocol for the promotion of one health was highlighted.


Subject(s)
Cat Diseases , Health Education , Ownership , Sporotrichosis , Animals , Cats , Cat Diseases/therapy , Cat Diseases/prevention & control , Cat Diseases/microbiology , Sporotrichosis/veterinary , Sporotrichosis/drug therapy , Sporotrichosis/prevention & control , Sporotrichosis/therapy , Humans , Female , Male , Antifungal Agents/therapeutic use
13.
Mycopathologia ; 189(3): 41, 2024 May 05.
Article in English | MEDLINE | ID: mdl-38704761

ABSTRACT

BACKGROUND: The global prevalence of invasive fungal infections (IFI) is increasing, particularly within Intensive Care Units (ICU), where Candida spp. and Aspergillus spp. represent the most important pathogens. Diagnosis and management of IFIs becomes progressively challenging, with increasing antifungal resistance and the emergence of rare fungal species. Through a consensus survey focused on assessing current views on how IFI should be managed, the aim of this project was to identify challenges around diagnosing and managing IFIs in the ICU. The current status in different countries and perceived challenges to date amongst a multidisciplinary cohort of healthcare professionals involved in the care of IFI in the ICU was assessed. METHODS: Using a modified Delphi approach, an expert panel developed 44 Likert-scale statements across 6 key domains concerning patient screening and minimal standards for diagnosis of IFIs in ICU; initiation and termination of antifungal treatments and how to minimise their side effects and insights for future research on this topic. These were used to develop an online survey which was distributed on a convenience sampling basis utilising the subscriber list held by an independent provider (M3 Global). This survey was distributed to intensivists, infectious disease specialists, microbiologists and antimicrobial/ICU pharmacists within the UK, Germany, Spain, France and Italy. The threshold for consensus was set at 75%. RESULTS: A total of 335 responses were received during the five-month collection period. From these, 29/44 (66%) statements attained very high agreement (≥ 90%), 11/44 (25%) high agreement (< 90% and ≥ 75%), and 4/44 (9%) did not meet threshold for consensus (< 75%). CONCLUSION: The results outline the need for physicians to be aware of the local incidence of IFI and the associated rate of azole resistance in their ICUs. Where high clinical suspicion exists, treatment should start immediately and prior to receiving the results from any diagnostic test. Beta-D-glucan testing should be available to all ICU centres, with results available within 48 h to inform the cessation of empirical antifungal therapy. These consensus statements and proposed measures may guide future areas for further research to optimise the management of IFIs in the ICU.


Subject(s)
Antifungal Agents , Intensive Care Units , Invasive Fungal Infections , Humans , Invasive Fungal Infections/drug therapy , Invasive Fungal Infections/diagnosis , Antifungal Agents/therapeutic use , Europe , Surveys and Questionnaires , Consensus , Disease Management
14.
Front Immunol ; 15: 1361277, 2024.
Article in English | MEDLINE | ID: mdl-38711522

ABSTRACT

In the late stages of the COVID-19 pandemic, there's an increasing trend in opportunistic infections, including bacterial and fungal infections. This study discusses the treatment process of two cases of cryptococcal meningitis during the COVID-19 pandemic. It highlights the importance of laboratory testing for these co-infections and stresses the need for vigilance, early diagnosis, and proactive treatment to improve patient outcomes in the post-pandemic era.


Subject(s)
Antifungal Agents , COVID-19 , Meningitis, Cryptococcal , SARS-CoV-2 , Humans , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/diagnosis , COVID-19/complications , COVID-19/epidemiology , Male , Antifungal Agents/therapeutic use , Middle Aged , Female , Coinfection , Adult , Cryptococcus neoformans/isolation & purification , Treatment Outcome
15.
Front Cell Infect Microbiol ; 14: 1322847, 2024.
Article in English | MEDLINE | ID: mdl-38707513

ABSTRACT

The aetiology of chronic aseptic meningitis is difficult to establish. Candida meningitis in particular is often diagnosed late, as cerebrospinal fluid (CSF) work-up and imaging findings are nonspecific. A 35-year-old patient with chronic aseptic meningitis, for which repeated microbiological testing of CSF was unrevealing, was finally diagnosed with Candida albicans (C. albicans) meningitis with cauda equina involvement using metagenomic next-generation sequencing (mNGS). This report highlights the diagnostic challenges and the difficulties of treating shunt-associated fungal meningitis.


Subject(s)
Candida albicans , High-Throughput Nucleotide Sequencing , Meningitis, Fungal , Metagenomics , Humans , Adult , Candida albicans/genetics , Candida albicans/isolation & purification , Meningitis, Fungal/diagnosis , Meningitis, Fungal/microbiology , Meningitis, Fungal/drug therapy , Metagenomics/methods , Candidiasis/diagnosis , Candidiasis/microbiology , Candidiasis/cerebrospinal fluid , Male , Chronic Disease , Antifungal Agents/therapeutic use , Meningitis, Aseptic/diagnosis
16.
J Med Life ; 17(1): 28-34, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38737667

ABSTRACT

This study assessed the efficacy of antimicrobial photodynamic therapy (PDT) using a 650 nm diode laser combined with methylene blue (MB) as a photosensitizer to inhibit the growth of Candida albicans (C. albicans). Oral samples were collected from 75 patients diagnosed with oral thrush. C. albicans was isolated and identified using traditional methods and the VITEK 2 YST system. Samples (n = 25) were divided into five groups: Group 1 (control, n = 5) consisted of C. albicans suspensions in saline; Group 2 (n = 5) treated with nystatin; Group 3 (n = 5) exposed to a 650 nm diode laser in continuous mode at 200 mW for 300 seconds; Group 4 (n = 5) treated with 650 nm laser and MB as a photosensitizer; Group 5 (n = 5) exposed to the laser in combination with nystatin. Statistical analysis using ANOVA, Dunnett's t-test (P = 0.05), and LSD (P = 0.001) revealed significant differences in C. albicans counts pre- and post-treatment. Group 5 showed the most significant reduction in C. albicans, followed by Group 4, while Groups 2 and 3 showed the least variation. The findings suggest that PDT using a 650 nm diode laser with methylene blue (in continuous mode at 200 mW for 300 seconds) effectively reduced the prevalence of C. albicans.


Subject(s)
Candida albicans , Methylene Blue , Photochemotherapy , Photosensitizing Agents , Candida albicans/drug effects , Photochemotherapy/methods , Humans , Methylene Blue/pharmacology , Photosensitizing Agents/pharmacology , Lasers, Semiconductor/therapeutic use , Candidiasis, Oral/drug therapy , Candidiasis, Oral/microbiology , Nystatin/pharmacology , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use
17.
Methods Mol Biol ; 2775: 13-27, 2024.
Article in English | MEDLINE | ID: mdl-38758308

ABSTRACT

Cryptococcal meningitis (CM) is a fungal disease caused by the invasion of Cryptococcus yeast cells into the central nervous system. The organism is thought to enter the body through the lungs and then escape due to dysregulation of the immune response. Multiple animal species have been used to model the infection and characterize CM including mice, rats, dogs, guinea pigs, and rabbits. The rabbit model has over 40 years of data and has been used to study host-pathogen interactions and the efficacy of antifungal therapeutics. The model begins with immune suppression to eliminate the lymphocytic cell population followed by direct infection of the central nervous system via an injection of a suspension of yeast cells into the cisterna magna. The organism remains in the CNS during the course of infection, and cerebrospinal fluid can be repeatedly sampled to quantify the burden of organism, measure drug levels in the CSF, profile the immune response in the CSF, and/or characterize the yeast cells. The rabbit model of infection is a robust experimental model for better understanding CM and Cryptococcus cellular behavior.


Subject(s)
Disease Models, Animal , Meningitis, Cryptococcal , Animals , Meningitis, Cryptococcal/immunology , Meningitis, Cryptococcal/microbiology , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/pathology , Rabbits , Cryptococcus neoformans , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Host-Pathogen Interactions/immunology , Cryptococcus/immunology
18.
Methods Mol Biol ; 2775: 29-46, 2024.
Article in English | MEDLINE | ID: mdl-38758309

ABSTRACT

Cryptococcus neoformans and Cryptococcus gattii are the predominant etiological agents of cryptococcosis, a particularly problematic disease in immunocompromised individuals. The increased clinical use of immunosuppressive drugs, the inherent ability of Cryptococcus species to suppress and evade host immune responses, and the emergence of drug-resistant yeast support the need for model systems that facilitate the design of novel immunotherapies and antifungals to combat disease progression. The mouse model of cryptococcosis is a widely used system to study Cryptococcus pathogenesis and the efficacy of antifungal drugs in vivo. In this chapter, we describe three commonly used strategies to establish cryptococcosis in mice: intranasal, intratracheal, and intravenous inoculations. Also, we discuss the methodology for delivering drugs to mice via intraperitoneal injection.


Subject(s)
Cryptococcosis , Cryptococcus neoformans , Disease Models, Animal , Animals , Cryptococcosis/microbiology , Cryptococcosis/drug therapy , Cryptococcosis/immunology , Mice , Cryptococcus neoformans/pathogenicity , Cryptococcus gattii/pathogenicity , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use
20.
Clin Lab ; 70(5)2024 May 01.
Article in English | MEDLINE | ID: mdl-38747920

ABSTRACT

BACKGROUND: The aim of the study was to improve the clinical cognition of leukemia-like reaction caused by voriconazole and granulocyte colony-stimulating factor and to avoid misdiagnosis or delayed diagnosis. METHODS: A case of drug analysis of Voriconazole combined with granulocyte colony stimulating factor was retrospectively analyzed and related literature was reviewed. RESULTS: Blood routine of the patient on July 29: WBC 13.48 x 109/L, neutrophil 85.3%, lymphocyte 13.4%, hemoglobin 111 g/L, platelet 285 x 109/L. Vancomycin was given to prevent intracranial infection. Lumbar puncture was performed on July 30, cerebrospinal fluid was sent for routine and biochemical examination, leukocytes were 0.15 x 109/L, monocytes 45%, polynuclear cells 55%, protein 1.172 g/L, Acinetobacter baumannii and Candida clorbicus were detected in sputum culture, vancomycin and meropenem static sites were given to prevent intracranial secondary infection. Fungi were detected in urine culture, and voriconazole was given to prevent fungal infection. Blood routine: White blood cell 0.61 x 109/L, neutrophil 23%, lymphocyte 73.8%, red blood cell 2.65 x 1012/L, hemoglobin 77 g/L, platelet 17 x 109/L, bone marrow was extracted after medication. Bone marrow images show poor myelodysplasia, with granulocytes dominated by protoearly cells. Subsequent flow cytometry, chromosomal karyotype, and fusion gene analysis were performed to exclude the possibility of leukemia. Flow cytometry showed that the proportion of myeloid primordial cells was not high, the granulocytes were mainly at the early and young stage, no abnormal phenotype was observed in erythrocytes, monocytes and NK cells, no obvious mature B lymphocytes were observed, and the ratio of CD4+/CD8+ was decreased. Karyotype results showed that there was no mitotic phase. The results of fusion gene analysis showed that the fusion gene was negative or lower than the detection sensitivity. Voliconazole was stopped first, and granulocyte colony stimulating factor was stopped 3 days later. Two weeks later, blood and bone marrow images basically recovered, white blood cell 7.88 x 109/L, neutrophil 46.3%, lymphocyte 48.2%, hemoglobin 126 g/L, platelet 142 x 109/L, bone marrow hyperplasia active. The proportion of three series is roughly normal. CONCLUSIONS: The reason for the occurrence of leukemia-like reaction in this patient was considered to be related to voriconazole and granulocyte colony stimulating factor, cessation of voriconazole and granulocyte colony stimulating factor, and recovery of blood and bone marrow images. In the clinical use of voriconazole and granulocyte colony stimulating factor, close attention should be paid to the drug interaction and individualized medication should be carried out to ensure the safety of medication.


Subject(s)
Antifungal Agents , Granulocyte Colony-Stimulating Factor , Voriconazole , Humans , Voriconazole/therapeutic use , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Male , Retrospective Studies , Middle Aged , Female , Leukemia/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...